NASDAQ:PRQR ProQR Therapeutics (PRQR) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free PRQR Stock Alerts $1.85 -0.14 (-7.04%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$1.84▼$2.0250-Day Range$1.83▼$2.3952-Week Range$1.11▼$3.29Volume96,428 shsAverage Volume228,065 shsMarket Capitalization$150.52 millionP/E RatioN/ADividend YieldN/APrice Target$3.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ProQR Therapeutics alerts: Email Address ProQR Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside82.4% Upside$3.38 Price TargetShort InterestHealthy0.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.08Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.37) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.81 out of 5 starsMedical Sector792nd out of 905 stocksPharmaceutical Preparations Industry378th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingProQR Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageProQR Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about ProQR Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.45% of the float of ProQR Therapeutics has been sold short.Short Interest Ratio / Days to CoverProQR Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProQR Therapeutics has recently increased by 7.99%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldProQR Therapeutics does not currently pay a dividend.Dividend GrowthProQR Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRQR. Previous Next 1.1 News and Social Media Coverage News SentimentProQR Therapeutics has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ProQR Therapeutics this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProQR Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of ProQR Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 32.65% of the stock of ProQR Therapeutics is held by institutions.Read more about ProQR Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ProQR Therapeutics are expected to decrease in the coming year, from ($0.37) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProQR Therapeutics is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProQR Therapeutics is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProQR Therapeutics has a P/B Ratio of 3.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ProQR Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.This Crypto bull market is not even halfway over About ProQR Therapeutics Stock (NASDAQ:PRQR)ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.Read More PRQR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRQR Stock News HeadlinesJune 6 at 3:42 AM | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by StockNews.comMay 13, 2024 | finance.yahoo.comShareholders in ProQR Therapeutics (NASDAQ:PRQR) are in the red if they invested five years agoMay 10, 2024 | markets.businessinsider.comProQR’s Axiomer Platform Technology Shows Promise: Analyst Maintains Buy Rating on Robust Editing Efficacy and Clinical Development PotentialMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Promising RNA Editing Technology and Solid Financial FootingMay 9, 2024 | finanznachrichten.deProQR Therapeutics N.V.: ProQR Announces First Quarter 2024 Operating and Financial ResultsMay 9, 2024 | globenewswire.comProQR Announces First Quarter 2024 Operating and Financial ResultsMay 8, 2024 | markets.businessinsider.comBuy Recommendation on ProQR’s Innovative RNA Editing Platform and Promising Clinical ProspectsMay 8, 2024 | stockhouse.comProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer(TM) RNA Editing Program Targeting NTCP for Cholestatic DiseasesMay 8, 2024 | finance.yahoo.comProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic DiseasesApril 24, 2024 | stockhouse.comProQR Highlights Upcoming Presentations on Axiomer(TM) RNA Editing at ASGCT 27th Annual MeetingApril 23, 2024 | globenewswire.comProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024April 22, 2024 | finance.yahoo.comProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual MeetingApril 22, 2024 | globenewswire.comProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual MeetingApril 21, 2024 | uk.investing.comProQR retains key patent for RNA editing technologyApril 20, 2024 | stockhouse.comProQR Achieves Successful Defense of New Challenge to its Axiomer(TM) IP PortfolioApril 19, 2024 | globenewswire.comProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP PortfolioApril 8, 2024 | finance.yahoo.comProQR Therapeutics N.V. (PRQR)March 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: ProQR’s Axiomer Platform Shows Promising Potential in CNS and Metabolic DisordersMarch 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Strong Financials and Promising RNA Editing PlatformMarch 14, 2024 | finance.yahoo.comProQR Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 13, 2024 | globenewswire.comProQR Announces Year End 2023 Operating and Financial ResultsFebruary 18, 2024 | finance.yahoo.comPRQR Mar 2024 2.500 callFebruary 16, 2024 | wsj.comProQR Therapeutics N.V.February 15, 2024 | finance.yahoo.comProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA EditingJanuary 30, 2024 | stocknews.com4 Biotech Stocks With Massive Buy PotentialSee More Headlines Receive PRQR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/07/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRQR CUSIPN/A CIK1612940 Webwww.proqr.com Phone(188) 166-7000FaxN/AEmployees156Year FoundedN/APrice Target and Rating Average Stock Price Target$3.38 High Stock Price Target$5.00 Low Stock Price Target$2.00 Potential Upside/Downside+82.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,430,000.00 Net Margins-260.75% Pretax Margin-258.78% Return on Equity-61.58% Return on Assets-19.43% Debt Debt-to-Equity RatioN/A Current Ratio3.11 Quick Ratio3.11 Sales & Book Value Annual Sales$7.05 million Price / Sales21.35 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book3.36Miscellaneous Outstanding Shares81,360,000Free Float74,521,000Market Cap$150.52 million OptionableOptionable Beta0.35 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Domenico Valerio Ph.D. (Age 68)Founder & Independent Chairman of Supervisory Board Comp: $80.46kMr. Daniel Anton de Boer (Age 41)Founder, CEO & Member of Management Board Comp: $1.3MMr. Rene K. Beukema (Age 60)Chief Corporate Development Officer, General Counsel & Member of Management Board Comp: $994.88kDr. Gerard Platenburg (Age 60)Co-Founder & Chief Scientific Officer Comp: $23.92kMr. Jurriaan Dekkers (Age 48)Chief Financial Officer Ms. Sheila Sponselee (Age 40)Chief People & Operations Officer Ms. Sarah Cue KielyVice President of Investor Relations & Corporate CommunicationsMs. Sandra van der KolkJunior Financial ControllerMore ExecutivesKey CompetitorsAerovate TherapeuticsNASDAQ:AVTEORIC PharmaceuticalsNASDAQ:ORICDianthus TherapeuticsNASDAQ:DNTHPharming GroupNASDAQ:PHARSavaraNASDAQ:SVRAView All CompetitorsInstitutional OwnershipVirtu Financial LLCSold 8,961 shares on 5/20/2024Ownership: 0.032%Ikarian Capital LLCBought 10,958 shares on 5/17/2024Ownership: 0.594%M28 Capital Management LPSold 891,102 shares on 5/15/2024Ownership: 1.253%EP Wealth Advisors LLCBought 11,500 shares on 5/14/2024Ownership: 0.014%Acadian Asset Management LLCBought 24,763 shares on 5/10/2024Ownership: 0.030%View All Institutional Transactions PRQR Stock Analysis - Frequently Asked Questions Should I buy or sell ProQR Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRQR shares. View PRQR analyst ratings or view top-rated stocks. What is ProQR Therapeutics' stock price target for 2024? 4 brokers have issued 1-year target prices for ProQR Therapeutics' stock. Their PRQR share price targets range from $2.00 to $5.00. On average, they predict the company's stock price to reach $3.38 in the next twelve months. This suggests a possible upside of 82.4% from the stock's current price. View analysts price targets for PRQR or view top-rated stocks among Wall Street analysts. How have PRQR shares performed in 2024? ProQR Therapeutics' stock was trading at $1.98 on January 1st, 2024. Since then, PRQR shares have decreased by 6.6% and is now trading at $1.85. View the best growth stocks for 2024 here. When is ProQR Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our PRQR earnings forecast. How were ProQR Therapeutics' earnings last quarter? ProQR Therapeutics (NASDAQ:PRQR) issued its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.02. The biopharmaceutical company had revenue of $4.83 million for the quarter, compared to analysts' expectations of $3.31 million. ProQR Therapeutics had a negative net margin of 260.75% and a negative trailing twelve-month return on equity of 61.58%. What ETF holds ProQR Therapeutics' stock? Morningstar US Small Growth holds 21,680 shares of PRQR stock, representing 1.52% of its portfolio. What other stocks do shareholders of ProQR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX). Who are ProQR Therapeutics' major shareholders? ProQR Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include M28 Capital Management LP (1.25%), Ikarian Capital LLC (0.59%), Monaco Asset Management SAM (0.38%), BNP Paribas Financial Markets (0.04%), RFG Advisory LLC (0.04%) and Virtu Financial LLC (0.03%). How do I buy shares of ProQR Therapeutics? Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRQR) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.